MX2009007247A - Metodo para el tratamiento de afecciones asociadas con actividad aumentada de 5-lipoxigenasa y/o leucotrienos. - Google Patents
Metodo para el tratamiento de afecciones asociadas con actividad aumentada de 5-lipoxigenasa y/o leucotrienos.Info
- Publication number
- MX2009007247A MX2009007247A MX2009007247A MX2009007247A MX2009007247A MX 2009007247 A MX2009007247 A MX 2009007247A MX 2009007247 A MX2009007247 A MX 2009007247A MX 2009007247 A MX2009007247 A MX 2009007247A MX 2009007247 A MX2009007247 A MX 2009007247A
- Authority
- MX
- Mexico
- Prior art keywords
- increased
- lipoxygenase
- treatment
- conditions associated
- leukotriene activity
- Prior art date
Links
- 102000001381 Arachidonate 5-Lipoxygenase Human genes 0.000 title abstract 2
- 108010093579 Arachidonate 5-lipoxygenase Proteins 0.000 title abstract 2
- 230000000694 effects Effects 0.000 title abstract 2
- 150000002617 leukotrienes Chemical class 0.000 title 1
- MWLSOWXNZPKENC-ZETCQYMHSA-N 1-[(1s)-1-(1-benzothiophen-2-yl)ethyl]-1-hydroxyurea Chemical compound C1=CC=C2SC([C@@H](N(O)C(N)=O)C)=CC2=C1 MWLSOWXNZPKENC-ZETCQYMHSA-N 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 1
- MWLSOWXNZPKENC-SSDOTTSWSA-N zileuton Chemical compound C1=CC=C2SC([C@H](N(O)C(N)=O)C)=CC2=C1 MWLSOWXNZPKENC-SSDOTTSWSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Dermatology (AREA)
- Rheumatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pain & Pain Management (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Cardiology (AREA)
- Ophthalmology & Optometry (AREA)
- Oncology (AREA)
- Vascular Medicine (AREA)
- Communicable Diseases (AREA)
- Urology & Nephrology (AREA)
- Otolaryngology (AREA)
- Hematology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Diabetes (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US87927307P | 2007-01-05 | 2007-01-05 | |
| PCT/US2008/000101 WO2008085875A2 (en) | 2007-01-05 | 2008-01-04 | R-zileuton for use in conditions associated with increased 5-lipoxygenase and/or leukotriene activity (eg asthma) |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2009007247A true MX2009007247A (es) | 2009-09-18 |
Family
ID=39339861
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2009007247A MX2009007247A (es) | 2007-01-05 | 2008-01-04 | Metodo para el tratamiento de afecciones asociadas con actividad aumentada de 5-lipoxigenasa y/o leucotrienos. |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20100273868A1 (enExample) |
| EP (1) | EP2114399A2 (enExample) |
| JP (1) | JP2010515682A (enExample) |
| CN (1) | CN101674823A (enExample) |
| CA (1) | CA2674492A1 (enExample) |
| MX (1) | MX2009007247A (enExample) |
| WO (1) | WO2008085875A2 (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2490689A4 (en) * | 2009-10-19 | 2013-03-06 | Panmira Pharmaceuticals Llc | INJECTABLE FORMULATION FOR ADMINISTRATION IN OR NEAR RV |
| CN101829075B (zh) * | 2010-04-27 | 2011-07-20 | 中国人民解放军第三军医大学第一附属医院 | 苦柯胺a和苦柯胺b的用途 |
| WO2011137363A1 (en) | 2010-04-30 | 2011-11-03 | Allergan, Inc. | Novel treatment for age related macular degeneration and ocular ischemic disease associated with complement activation by targeting 5-lipoxygenase |
| CN102274213A (zh) * | 2010-06-10 | 2011-12-14 | 北京润德康医药技术有限公司 | 含有r(+)-齐留通的药用组合物 |
| EP2959899B1 (en) * | 2011-08-23 | 2017-02-22 | Cornerstone Therapeutics Inc. | Use of zileuton for the treatment of nasal polyps in cystic fibrosis patients |
| GB201118193D0 (en) * | 2011-10-21 | 2011-12-07 | Jagotec Ag | Improvements in or relating to oranic compounds |
| GB201118198D0 (en) * | 2011-10-21 | 2011-12-07 | Jagotec Ag | Improvements in or relating to organic compounds |
| CN102429872B (zh) * | 2011-11-25 | 2013-07-10 | 舒泰神（北京）生物制药股份有限公司 | 含齐留通的膜控型缓释微丸及其制备方法 |
| TW201615222A (zh) * | 2014-10-24 | 2016-05-01 | 朗齊生物醫學股份有限公司 | 免疫疾病用藥臨床新應用 |
| WO2016191520A1 (en) * | 2015-05-26 | 2016-12-01 | Memorial Sloan-Kettering Cancer Center | Ferroptosis and glutaminolysis inhibitors and methods of treatment |
| CA3202852A1 (en) * | 2020-12-01 | 2022-06-09 | Reverspah Llc | Methods and compositions for treating chronic obstructive pulmonary disease, asthma, pneumonia, bronchitis, cystic fibrosis and pulmonary edema, interstitial lung disease, sarcoidosis, idiopathic pulmonary fibrosis, a cute respiratory distress syndrome, and pulmonary arterial hypertension |
| WO2024044654A2 (en) * | 2022-08-23 | 2024-02-29 | University Of Houston System | Parenteral compositions of zileuton and methods of use |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1994026268A1 (en) * | 1993-05-10 | 1994-11-24 | Sepracor, Inc. | Methods and compositions using optically pure (+)-zileuton |
| EP2409973A1 (en) * | 2006-02-21 | 2012-01-25 | Critical Therapeutics, Inc. | New crystal form and pharmaceutical compositions of (+)-R-zileuton |
-
2008
- 2008-01-04 US US12/521,965 patent/US20100273868A1/en not_active Abandoned
- 2008-01-04 CA CA002674492A patent/CA2674492A1/en not_active Abandoned
- 2008-01-04 WO PCT/US2008/000101 patent/WO2008085875A2/en not_active Ceased
- 2008-01-04 CN CN200880004777A patent/CN101674823A/zh active Pending
- 2008-01-04 EP EP08712975A patent/EP2114399A2/en not_active Ceased
- 2008-01-04 JP JP2009544925A patent/JP2010515682A/ja active Pending
- 2008-01-04 MX MX2009007247A patent/MX2009007247A/es active IP Right Grant
Also Published As
| Publication number | Publication date |
|---|---|
| CA2674492A1 (en) | 2008-07-17 |
| CN101674823A (zh) | 2010-03-17 |
| WO2008085875A2 (en) | 2008-07-17 |
| JP2010515682A (ja) | 2010-05-13 |
| WO2008085875A3 (en) | 2009-02-26 |
| EP2114399A2 (en) | 2009-11-11 |
| US20100273868A1 (en) | 2010-10-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2009007247A (es) | Metodo para el tratamiento de afecciones asociadas con actividad aumentada de 5-lipoxigenasa y/o leucotrienos. | |
| WO2011014255A8 (en) | Treatment of crohn's disease with laquinimod | |
| PH12013500919B1 (en) | Vasoprotective and cardioprotective antidiabetic therapy | |
| MX2012000034A (es) | Metodos para el tratamiento o la prevencion de la fatiga. | |
| MX2019005130A (es) | Inhibidores de dpp-iv, tales como la linagliptina, y composiciones farmaceuticas o combinaciones que comprenden los mismos, para usarse en el tratamiento de pacientes diabeticos tipificados geneticamente. | |
| MX2010004450A (es) | Derivados heterociclo biciclicos y su uso como moduladores de la actividad de gpr119. | |
| MX2011007589A (es) | Tratamiento de un cancer usando una combinacion de bendamustine y un anticuerpo anti-cd20. | |
| PH12013500808A1 (en) | Pharmaceutical combinations for the treatment of metabolic disorders | |
| WO2011020061A3 (en) | Compositions and methods of for treating bipolar disorder | |
| MY153062A (en) | Methods of treating gastrointestinal disorders independent of the intake of food | |
| GEP201706786B (en) | Methods and drug products for treating alzheimer's disease | |
| WO2006127007A3 (en) | Methods of using adipose tissue-derived cells in the treatment of cardiovascular conditions | |
| WO2011041632A3 (en) | Combination therapies for the treatment of obesity | |
| WO2010151565A3 (en) | Combination therapies for the treatment of obesity | |
| MY159826A (en) | Treatment of cognitive disorders with (r)-7-chloro-n-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide and pharmaceutically acceptable salts thereof | |
| MX2010009624A (es) | Derivados de 1-bencil-3-hidroximetilindazol y uso de los mismos en el tratamiento de enfermedades basadas en la expresion de mcp-1 y cx3cr1. | |
| WO2010088450A3 (en) | Arylamide derivatives useful in the treatment of diseases associated with serca activity | |
| WO2010151503A3 (en) | Combination therapies for the treatment of obesity | |
| WO2011044523A3 (en) | Compositions and methods for treating obesity | |
| NZ595364A (en) | TISSUE KALLIKREIN FOR THE TREATMENT OF PANCREATIC beta-CELL DYSFUNCTION | |
| MX2010008433A (es) | Uso de ranolazina para el tratamiento de enfermedades cardiovasculares. | |
| WO2010045522A3 (en) | Combination therapies for the treatment of obesity | |
| MX2012002161A (es) | El uso de lapatinib o una sal o composición farmacéuticamente aceptable del mismo para el tratamiento de cancer. | |
| MX2008002456A (es) | Uso de ambroxol para el tratamiento de infecciones por rinovirus. | |
| WO2010117992A3 (en) | Coupled identification and treatment of cancer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |